MarketLens

Roche's Divarasib: A New Standard of Care Emerges to Challenge Amgen's KRAS Dominance

2 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

1 months ago

Together AI's $8.3 Billion Valuation: A Neocloud's Challenge to Hyperscaler AI Dominance

2 months ago

What's Driving Amgen's Recent Volatility

4 months ago

Has Accel Entertainment's Recent Performance Set a New Standard

6 months ago

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

Revolution Medicines (RVMD) secured rapid FDA approval for RASONQUE, a first-in-class oral RAS(ON) inhibitor for metastatic pancreatic cancer, positioning it as a potential blockbuster. Despite a $3.9...

RVMD

Stock News•1 months ago

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

The race for the next standard cancer treatment is focusing on pairing two innovations, as the market looks beyond Merck's Keytruda.

MRK

Stock News•2 months ago

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Erasca's ERAS-0015 showed 57% uORR in 2L KRAS G12X pancreatic cancer at 32 mg QD RDE, with 100% median relative dose intensity. Company plans registration-enabling lung cancer trial in H1 2027 and Pha...

ERAS

Breaking News

Clinical Trials (Phase I, II, III)

Creator Economy

Crude Oil (WTI/Brent)

Top Headlines

View More →

Stock News•2 hours ago

Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.

Stock News•2 hours ago

Viral AI Dommer Tweet: Engineered Panic?

Stock News•3 hours ago

Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.

Stock News•4 hours ago

Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.

Stock News•6 hours ago

Roche's Divarasib: A New Standard of Care Emerges to Challenge Amgen's KRAS Dominance

Exclusive Content for Pro Members

Related Articles

Gilead and Merck's Weekly HIV Pill: A New Standard of Care Emerges

Together AI's $8.3 Billion Valuation: A Neocloud's Challenge to Hyperscaler AI Dominance

What's Driving Amgen's Recent Volatility

Has Accel Entertainment's Recent Performance Set a New Standard

Category

You may also like

Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Erasca Announces Updated Preliminary Phase 1 Data and Registration-Enabling Plans for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Cybersecurity Is the Next Big Market for Artificial Intelligence (AI), According to Jensen Huang. This Super Stock-Split Stock Is the One to Own.

Viral AI Dommer Tweet: Engineered Panic?

Jeff Bezos Built Amazon Into a $1.8 Trillion Company. Here's How Andy Jassy Is Making It Worth Even More.

Apple Bought Back More Than $880 Billion of Its Own Stock During Tim Cook's 15 Years as CEO. Here's How That Reshaped Shareholder Returns.

Warren Buffett Made Apple Berkshire Hathaway's Single Largest Stock Position: $10,000 Invested 10 Years Ago Would Be Worth Roughly $122,400 Today